Literature DB >> 31741022

An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy.

Majid Assadi1, Reza Nemati2, Hossein Shooli3, Seyed Javad Rekabpour4, Iraj Nabipour5, Esmail Jafari3, Ali Gholamrezanezhad6, Abdullatif Amini7, Hojjat Ahmadzadehfar8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31741022     DOI： 10.1007/s00259-019-04578-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  8 in total

1.  Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis.

Authors:  Mojtaba Ghasemi; Iraj Nabipour; Abdolmajid Omrani; Zeinab Alipour; Majid Assadi
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-11-30

Review 2.  Personalized & Precision Medicine in Cancer: A Theranostic Approach.

Authors:  Partha Choudhury; Manoj Gupta
Journal:  Curr Radiopharm       Date:  2017-11-10

Review 3.  PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.

Authors:  Sandip Basu; Abass Alavi
Journal:  PET Clin       Date:  2016-05-02

4.  Precipitating factors in pituitary apoplexy.

Authors:  V Biousse; N J Newman; N M Oyesiku
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

5.  Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma.

Authors:  Jan Komor; Jean Claude Reubi; Emanuel R Christ
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

6.  First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.

Authors:  S Baldari; F Ferraù; C Alafaci; A Herberg; F Granata; V Militano; F M Salpietro; F Trimarchi; S Cannavò
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

7.  Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.

Authors:  Jillian Maclean; Matthew Aldridge; Jamshed Bomanji; Susan Short; Naomi Fersht
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

8.  Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function.

Authors:  Jaap J M Teunissen; Eric P Krenning; Frank H de Jong; Yolanda B de Rijke; Richard A Feelders; Maarten O van Aken; Wouter W de Herder; Dik J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-27       Impact factor: 9.236
  8 in total
  2 in total

Review 1.  Aggressive pituitary tumours and pituitary carcinomas.

Authors:  Gérald Raverot; Mirela Diana Ilie; Hélène Lasolle; Vincent Amodru; Jacqueline Trouillas; Frédéric Castinetti; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2021-09-07       Impact factor: 43.330

Review 2.  Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.

Authors:  Tae Nakano-Tateno; Kheng Joe Lau; Justin Wang; Cailin McMahon; Yasuhiko Kawakami; Toru Tateno; Takako Araki
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-26       Impact factor: 5.555
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.